THERAPIX BIOSCI/S (NASDAQ:TRPX) released its quarterly earnings data on Monday. The company reported ($0.35) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.24, Fidelity Earnings reports.
NASDAQ:TRPX opened at $3.60 on Tuesday. THERAPIX BIOSCI/S has a fifty-two week low of $3.00 and a fifty-two week high of $7.69. The stock has a market cap of $12.48 million, a PE ratio of 1.68 and a beta of 1.07.
About THERAPIX BIOSCI/S
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110 for the treatment of Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for the treatment of Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
See Also: Analyst Ratings
Receive News & Ratings for THERAPIX BIOSCI/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for THERAPIX BIOSCI/S and related companies with MarketBeat.com's FREE daily email newsletter.